



February 24, 2025

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Scrip Code: **530019**

Symbol: **JUBLPHARMA**

Sub.: Presentation for Investor and Analyst Meet

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

In continuation of our letter dated January 27, 2025, regarding the Investor and Analyst Meet scheduled to be held later during the day i.e. Monday, February 24, 2025, please find enclosed the presentation that will be discussed during the meeting.

The above details will also be available on the website of the Company at www.jubilantpharmova.com.

Kindly take the above information on records.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

Encl. as Above

A Jubilant Bhartia Company


OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624



**Investor & Analyst Meet
Feb'25**

Disclaimer



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Executive Leadership Team



Shyam S Bhartia
Chairman



Hari S Bhartia
Co-Chairman



Priyavrat Bhartia
Managing Director



Arjun S Bhartia
Joint Managing Director



Arvind Chokhany
Group CFO, Whole-time Director



Shantanu Jha
Group CHRO



Dr Tushar Gupta
Head - Corporate Strategy

Executive Leadership Team



Harsher Singh
CEO - Jubilant Radiopharma



Chris Preti
CEO - CDMO Sterile Injectables



Giuliano Perfetti
CEO - CRDMO, Biosys



Dr Jaidev Rajpal
CEO - Jubilant Generics



Kyle Ferguson
CEO - Allergy Immunotherapy



Dr Syed Kazmi
CEO - Jubilant Therapeutics

Agenda

Overview	Arjun Bhartia
Vision 2030	Priyavrat Bhartia
Radiopharma	Harsher Singh
CDMO Sterile Injectables	Chris Preti
CRDMO	Giuliano Perfetti
Allergy Immunotherapy	Kyle Ferguson
Generics	Dr Jaidev Rajpal
Proprietary Novel Drugs	Dr Syed Kazmi
Summary	Arvind Chokhany
Q&A – starts at 7 pm	Management Panel

Overview



Arjun S Bhartia Joint Managing Director

Jubilant Bhartia Group has created value across multiple sectors



Mr. Hari S Bhartia
Co-Chairman

Mr. Shyam S Bhartia
Chairman



Strong presence in diverse sectors

- Pharmaceuticals
- Life Science Ingredients
- Performance Polymers
- Food Service (QSR)
- Contract Research & Development Services
- Therapeutics
- Auto Dealerships
- Oil and Gas services



Global presence through investments

- India
- USA
- Canada
- Europe
- Singapore
- Australia
- Africa
- China
- Sri Lanka, Bangladesh



Employer of Top Talent

43,000 people across the globe with ~2,200 in North America

Jubilant Pharmova, a diversified pharmaceutical company



Radiopharma

Leading manufacturer
of Radiopharmaceuticals
in North America

2nd largest radiopharmacy network in the US



Allergy Immunotherapy

2nd largest player
in the US Allergenic extract market
Sole supplier of Venom
Immunotherapy in the US



CDMO Sterile Injectables

Leading contract manufacturer
in North America
Serves top global innovator pharma
companies




CRDMO

Integrated drug discovery
and development service provider
Formidable API player
in multiple therapeutic areas



Generics

Over 50 countries served
including regulated markets
Broad therapeutic areas :
CVS, CNS, GI and MS



Proprietary Novel Drugs


Two drug programs
in clinical trials
Developing high potential precision
medicines in Oncology

**A global leader with a
strong team of 5,500
people**

Focus on specialty products & services and North American market

Business wise Revenue Split


FY24



Specialty Products (Radiopharma, Allergy Immunotherapy) and Specialty Services (CDMO & CRDMO) contribute majority of revenues

Geography wise Revenue Split

FY24



Majority (~90%) revenues are USD denominated

State-of-the-art manufacturing and research facilities enable our growth

NORTH AMERICA

Kirkland, Montreal, Canada
CDMO – Sterile Injectables Radiopharmaceuticals



Spokane, Washington, US
CDMO – Sterile Injectables Allergy Immunotherapy



INDIA

Roorkee, Uttarakhand, India - Generics



Nanjangud, Karnataka, India - CDMO API



G. Noida, Uttar Pradesh - Drug discovery



Bengaluru, Karnataka - Drug discovery

6
Manufacturing
facilities

2
Research facilities

46
Radiopharmacies

Committed to high standards of quality



Business	Location	US FDA Status
Radiopharmaceutical	Montreal, Canada	VAI Apr, 2024
Allergy Immunotherapy	Spokane, US	VAI Sep, 2024
CDMO-Sterile Injectables	Spokane, US	VAI Sep, 2024
CRDMO API	Nanjangud, India	VAI Mar, 2023
Generics	Roorkee, India	VAI Apr, 2024
CDMO-Sterile Injectables	Montreal, Canada	OAI - untitled Sep, 2024

Relentless focus on quality

- Anytime audit readiness
- Bottoms - up quality culture
- Continuous investments in infrastructure

Vision 2030




Priyavrat Bhartia Managing Director

Delivered strong financial performance

FY23 - TTM' Dec'24 Progress

Revenue : **Rs. 6,282 Cr.**
EBITDA Margin : **13.1%**
Net Debt/ EBITDA : **2.9x**

Revenue : **Rs. 7,064 Cr.**
EBITDA Margin : **16.3%**
Net Debt/ EBITDA : **1.4x**



- **Strengthened quality culture**
- **Investment in people and leadership**
- **Transformed Generics and Radiopharmacies**

Vision 2030: We aspire to double our revenues by FY30



	From FY24	→	To FY30*
2x Revenue	Rs. 6,703 Cr.		Rs. 13,500 Cr.
25% EBITDA Margin	~ 15 %		23% to 25%
Zero Net Debt	Rs. 2,457 Cr.		Zero
High Teens RoCE	High Single digit		High Teens

* Future numbers projected on constant currency basis

These are our growth drivers to achieve Vision 2030

Business	Growth Drivers
Radiopharma	Leadership in Ruby-Fill® Launch New PET, SPECT and Therapeutic products (MIBG) Invest in 6 high margin PET Radiopharmacies in US
CDMO - Sterile Injectables	Double capacity in Spokane, US
CRDMO	Add large pharma customers Grow CDMO and custom manufacturing in API
Allergy Immunotherapy	Strengthen competitive position and develop new products
Generics	Launch new products in the US and Grow profitable Non-US international business

A medical professional in blue scrubs is adjusting a patient on a CT scanner. The patient is lying on a table, and the scanner's gantry is visible in the background. The scene is set in a clinical environment with medical equipment and a patient. The word "Radiopharma" is overlaid in white text on a dark blue rounded rectangle.

Radiopharma



Harsher Singh CEO - Jubilant Radiopharma

Radiopharmaceuticals



**SPECT
Imaging**

Low Energy
gamma rays
detected by SPECT cameras

Isotopes - Tc99m

Key Products

MAA, DTPA, Sulfur Colloid,
Mertiatide



**PET
Imaging**

High Energy
positrons
detected by a PET scanner

Isotopes - Rb82, F18, Ga68

Ruby-Fill[®], Pylarify, Illuccix,
Neuraceq, FDG



**Radiopharmaceutical
Therapeutics**

**Systemically or Locally
Delivered**
radiation using pharmaceuticals


Isotopes – I131, Lu177, Ac225

HICON[®] Sodium Iodide
I 131, Pluvicto, Lutathera

**Radiopharmaceuticals have a growing role in treatment of life-threatening diseases
e.g. Cancer**

US Radiopharmaceutical market is growing at 20% CAGR

US Radiopharmaceutical Market USD Bn.



Growth Drivers & Trends

- PSMA Therapeutic, Pluvicto for Prostrate Cancer ~USD 2.0 Bn.
- PSMA Diagnostics for Prostrate Cancer ~ USD 1.5 Bn.
- Broad range of applicability e.g. Alzheimer's
- Special reimbursement for diagnostic products (FIND Act)
- Novartis and Mariana Oncology (USD 1 Bn.)
- AstraZeneca and Fusion (USD 2.4 Bn.)
- Lilly and Point Biopharma (USD 1.4 Bn.)
- BMS and Rayzebio (USD 3.6 Bn.)

PET imaging & advance therapies are driving the market growth


We are a leading Radiopharmaceuticals manufacturer in North America



	Organ	Key Indication	Product
PET Dx	Cardiac	Coronary Artery disease	Ruby - Fill®
	Breast	Lymph nodes detection	Sulfur Colloid
SPECT Dx	Cardiac	Cardiac blood pool imaging	Tc99m-Gluceptate
		Coronary Artery Disease	Tc99m-Sestamibi
	Gastrointestinal	Intra-abdominal Infection	Tc99m-Exametazime
	Lung	Pulmonary Embolism	Tc99m-DTPA
		Pulmonary Perfusion	Tc99m-MAA
	Muscoskeletal	Altered osteogenesis	Tc99m-MDP
	Renal	Renal failure	Tc99m-Mertiatide
	Thyroid	Localising thyroid malignancies	I-131
Therapeutics	Thyroid	Hyperthyroidism, Thyroid Cancer	I-131 HICON®

- Diversified across diagnostics & therapeutics
- Current TAM at USD 400 Mn.
- Strong R&D and supply chain
- In-house API manufacturing

Radiopharmaceuticals Vision 2030: To more than double the revenues



Growth drivers:

- Ruby-Fill®
- New PET & SPECT products
- MIBG

To become leader in cardiac PET Imaging through Ruby-Fill®

Ruby-Fill® Rubidium 82 generator and Elusion System



Competitive advantage

- Longer life per generator (7 weeks vs 6 weeks for peer)
- Better image quality and consistency
- Saline Push feature

Current Position

- Market Size ~ USD 160 Mn. and growing at 12%
- Market share ~ 25% and growing

Product Innovation

- Value engineering to lower cost & improve margin
- AI enabled 3D cardiac blood flow quantification

Growth drivers:

- Ruby-Fill®
- New PET & SPECT products
- MIBG

Launch new PET and SPECT imaging products with a TAM of USD 550 Mn

Developing new products in SPECT Imaging to maintain leadership & in PET Imaging for growth



Timeline	Incremental TAM USD Mn.	Potential Peak Annual Sales - USD Mn.	No. of launches
FY27	50	20	2
FY28	250	60	3
FY29	250	40	4
Total	550	120	9

Growth drivers:

- Ruby-Fill®
- New PET & SPECT products
- MIBG

Launch MIBG by FY27

Growth drivers:


- Ruby-Fill®
- New PET & SPECT products
- MIBG

HICON® Sodium Iodide I 131 - Commercialised



- Iodine I 131, HICON® is standard care for patients
- Used for diagnosis and treatment of Thyroid cancer

MIBG - Undergoing Clinical trials




- Used in imaging & treatment for pediatric cancer - Neuroblastoma
- Relapsed / Refractory patients have limited treatment options

- Potential peak sales USD 70 - 100 Mn.
- Data package to FDA by H2'FY26



Radiopharmacy



61 Pm Promethium	62 Sm Samarium	63 Eu Europium	64 Gd Gadolinium	65 Tb Terbium	Dy Dysprosium	Ho Holmium
93 Np Neptunium	94 Pu Plutonium	95 Am Americium	96 Cm Curium	97 Bk Berkelium	98 Cf Californium	99 E Einsteinium

Radiopharmacies are critical in generating value

SPECT Radiopharmacy



PET Radiopharmacy



Growth Drivers & Trends

- **Large M&A transactions** in Radiopharmacies
- **Increasing demand for novel PET products** driving PET radiopharmacies growth
- **Stringent USP 825 regulations** to drive increase in therapeutics dispensing through Pharmacy

The 2nd largest radiopharmacy network in the US



46
Radiopharmacies
with ~ **20%**
volume market
share




1,800
hospitals
catered



6 customized
doses delivered
every
minute



99%+
on-time deliveries,
Use of AI for route
optimization



USP<825>
*JDR network is USP 825
compliant*



Business moat
Unique combination of
SPECT manufacturing &
radiopharmacy network




6
Planning new sites in
PET network



Therapeutics
distribution is preferred
from radiopharmacies

Radiopharmacy Vision 2030: Double the revenues, expand margins by adding 6 PET Radiopharmacies



Expanding PET Radiopharmacy network from current 3 sites to 9 sites

Growth driver:

- PET expansion



- **Strengthened network to enable long term contracts** with PET radiopharmaceutical manufacturers
- **Fully operational by FY28.** Funding through internal accruals and long-term credit
- **Expect Asset turnover of 1.0x and RoCE 20% +** on the USD 50 Mn. investment

CDMO - Sterile Injectables




Chris Preti CEO - CDMO Sterile Injectables

CDMO - Sterile Injectables is seeing demand supply gap widening

Global CDMO-SI Market Size

USD Bn



Vial filling (Units in Billions)

Year	2023	2024	2025	2026	2027
Demand	4.9	5.2	5.7	6.2	6.8
Supply	5.5	5.8	6.1	6.1	6.1

**Demand supply gap of 700 Mn. vials in 2027,
to be further widened by industry consolidation**

Growth Drivers & Trends


- **Increasing number of drugs** in Biologics pipeline and Loss of exclusivity
- **Consolidation in supply** due to large acquisitions - Catalent Inc. by Novo Holding
- **Reduction in offshoring** by innovators due to regulatory and supply chain advantages

We are a leading North American CDMO player with unique capabilities and strong customer relationships



- **5 of the top 20** pharma companies as customers
- **5+ years** average relationship time with Top 10 Customers
- **90%+** repeat customer business
- **24 months** of switching timelines for customers
- **10+ years of US FDA compliant status** at flagship site in Spokane


CDMO - Sterile Injectables Vision 2030 : Double revenues by doubling of capacity at Spokane



New lines have incremental revenue potential of USD 160 Mn. to USD 180 Mn.

Growth driver:

- Doubling Capacity



- Total investment at USD 285 Mn. (RoCE > 20%) including US Govt. funding of USD 150 Mn.
- **Multiple technology transfers underway. Commercial revenue from Line 3 by FY26 / FY27**

CRDMO: Drug Discovery Services, CDMO API

Giuliano Perfetti CEO - CRDMO, Biosys




CRDMO: Drug Discovery, CDMO - API

India uniquely positioned to benefit from Friendshoring



Drug Discovery Services Market Size

USD Bn.



CDMO API Market Size

USD Bn.



Growth Drivers & Trends

Drug Discovery Market

- Biosecure Act advantage
- Rise in specialized technologies such as ADCs and oligonucleotides

CDMO API Market

- Rising interest in custom generics
- Rapid momentum in specialized CDMO services

We are a leading CRDMO for science with superior customer relationships



- **8 of the top 20 pharma** companies as customers with 5x increase in revenue share from large pharma
- **Indian Leader for “Integrated Drug Discovery”**, with a track record of +85 programs and Big pharma strategic partnership
- **Strengthen European penetration**, with multifold revenue increase
- **Fully integrated Chemistry powerhouse** from mg to multi-tons
- **Successful launch of new CDMO services** for Biotech and Large Pharma

...with state of the art integrated CRDMO platform

Drug Discovery Services & Early CDMO

Late CDMO & APIs



**CoE Biologics
(St. Julien, France)**

**Integrated
Drug Discovery Centre
(IDDC, Bengaluru)**

**Chemistry Research
Innovation Centre
(CIRC, G. Noida)**

**Contract Development &
Manufacturing Centre
(API CDMC)**

**Advanced Intermediate
&
API Manufacturing**

~ 35 Scientists

~ 250 Scientists

~ 700 Scientists

~300 Scientists

900+ MT of capacity

Antibody Drug
Conjugates, Biologics

Identifying target to
candidate selection

Synthetic, Medicinal,
Analytical and
Computational Chemistry

Process Research Chemistry
& Manufacturing

US FDA, Japan PMDA,
Korea KFDA, Brazil ANVISA

**Immune - oncology
Expertise**


**+85
Integrated Programs
delivered**

**~40 clients
in last 3 years**

**From mg to kg
Supporting Scale-up up to
20 kg**


**Potent API expertise
OEB Class 1-3 API potency**

Drug Discovery Vision 2030 : Triple revenues & maintain profitability



Growth driver:

- Add large pharma



Biosecure Act

- Act passed in Sep'24 by US House of Representatives
- American pharma companies to look for alternatives besides China

- Executing strategy on large pharma
- Footprint in EU
- Introduction of ADCs, mAbs, and Biologics platforms

Drug Discovery Services: Expansion at current and new sites to enable revenue growth

Expansion at current sites, Greater Noida & Bengaluru



Expansion at new site, Devanahalli, Bengaluru



Capacity : 1,000 FTE's (FY25) → 2,000 FTE's (FY26) → 4,000 FTE's (FY27)


Total Capex USD 150 Mn. (Expect RoCE > 20%)

Drug Discovery Services: Added capability in Biologics through strategic partnership with Pierre Fabre



- Expanded TAM by USD 1.4 Bn. in mAbs and ADCs
- Added strategic footprint in the EU
- Enhanced domain expertise in ADC
- Unique & cost-effective delivery model

API Vision 2030 : Double revenues and increase profitability



Growth driver:

- Grow CDMO API



- **Further Strengthen CDMO:** Leverage GMP manufacturing capabilities for Innovative New Chemical Entities
- **Custom Manufacturing:** Partner with large pharma to manufacture products requiring life cycle management
- **China plus one strategy:** Resilient supply chain through increased backward integration & diversified supplier base

Allergy Immunotherapy



Kyle Ferguson CEO – Allergy Immunotherapy

Allergy immunotherapy is the sole way to fundamentally reduce allergen hypersensitivity

- 20% + global population have allergies e.g. Asthma and Allergic Rhinitis
- Allergy Immunotherapy requires repeated shots of allergic antigens to develop immunity

Allergies



Testing




Treatment



Global Allergy Immunotherapy market is expected to grow by ~ 7%

Global Allergy Immunotherapy Market USD Bn.



Growth Drivers and Trends

- **Concentrated US market** with 3 players
- **Complex supply chain** from sourcing to processing
- **Grandfathered approvals**, new product needs BLA
- **Market increasing** in Sub-Lingual delivery
- **Challenging reimbursement** landscape

2nd largest player in the US Sub-Cutaneous Allergy Immunotherapy market

- 100-year-old 'HollisterStier' brand
- Sole Supplier of Venom extracts in the US
- 200+ allergenic & 6 venom extracts
- Onshore US FDA approved manufacturing
- Dedicated sales force in the US
- 2,000+ Allergists / ENTs as customers

Venom Extracts



Venom extracts for Honey Bee and other insects

Allergenic Extracts




Allergenic extracts for Dog, Cat, Mite, Tree, Pollen etc.

Skin Testing Devices



Multiple skin testing systems

Allergy Immunotherapy Vision 2030: Solidify position as a scientific leader



Allergy Immunotherapy Growth Drivers

Strengthen competitive position in US

- Retain and grow **Venom** customers & patient base
- Increase US revenue in **Allergenic extracts** through targeted marketing



Grow outside US business

- Increase outside US **Venom** sales through strategic partnerships in European markets



Increase investment in R&D

- Develop new products & technologies
- Build treatment **innovation** through partnerships and alliances

Generics




Dr Jaidev Rajpal CEO - Jubilant Generics

Global Generics market expected to grow by ~ 5% to 6%



Generics Market USD Bn



Growth Drivers and Trends


Developed Market

- US market to grow at 2%, signs of decrease in price reductions
- Non-US market to grow by 5 - 7%


India Market

- India market to grow in excess of 8%
- Brand building, in-clinic effectiveness of sales is key

We are building a growing, profitable & agile business model



Generics Vision 2030 : Reached profitability, aim to reach top quartile profitability for similar size companies



Generics Growth Drivers



Launch new products

- Relaunch dormant ANDAs from Roorkee and CMO network
- Secure ANDAs (33) approvals



Grow the profitable Non-US international market

- Launch 6 to 8 new products every year
- Scale 3 to 4 key markets



Build branded business


- Build presence in Diabetes, Dyslipidemia and Hypertension
- Scale in weight management
- Grow 1.5 times the Industry growth rate

Proprietary Novel Drugs




Dr Syed Kazmi CEO - Jubilant Therapeutics

Proprietary Novel Drugs




- **Develop precision oral medicines** with enhanced safety and therapeutic efficacy
- **Focused on specific set of patients**, not responding to other therapies
- **Low-cost in-house discovery engine** to generate drug candidates, validated through partnerships
- **Guided by world's leading oncologists** from Memorial Sloan Kettering and Dana Farber
- **FDA Orphan drug designations** for leading programs JBI-802 and JBI-778

JBI-802 to address unmet medical needs in difficult to treat cancers




- **Company sponsored Phase II trial underway**
- Highly differentiated for safety and efficacy than peers
- Total Addressable Market in US: USD 3.3 Bn.
- **Investigator led trial under planning**
- Demonstrated clinical efficacy in two NSCLC patients in phase 1 study
- Total Addressable Market in US: USD 3.1 Bn.
- **Investigator led trial under planning**
- Blood cancer progression to Leukemia is a serious complication
- Total Addressable Market in US: USD 0.8 Bn.

JBI -802 has demonstrated transformative treatment in two patients



- Non small cell lung cancer patient progressed to last stage after immunotherapy. Post taking JBI-802 treatment, patient has been doing very well even after two years. Major symptoms have disappeared with confirmed partial response with **~40% tumor reduction**
- **Over 50% shrinkage of the patient's liver metastasis** and a complete resolution of related portal hypertension and improvement in quality of life

JBI-778 to address unmet medical needs in difficult to treat cancers



Proprietary Novel Drugs to explore monetization



- Expect clinical data readouts from CY 2025 to CY 2026
- **Explore monetization through licensing or external fund raising**

Summary



Arvind Chokhany Group CFO, Whole-time Director

Investment Thesis

- 1 **Supportive Industry tailwinds** in Radiopharma, CDMO & CRDMO
- 2 **High entry barriers or clear differentiation** in each business
- 3 **Specialist management** to drive each business
- 4 **Robust risk management** with specific focus on quality & compliance

Jubilant Pharmova Limited has delivered 169% return, outpacing NIFTY returns



Jubilant Pharmova Limited Stock Return
FY23 - FY24 - 9M'FY25



Sustainability is at the core of our operations

Environment

- **42%** reduction¹ in greenhouse gas emission
- **23%** reduction¹ in specific water consumption
- **Zero Liquid Discharge** at all Indian plants
- **25%** reduction¹ in specific energy consumption

Social

- **23%+ women** in global workforce
- **Assessment of new suppliers** on sustainability
- **23,709 patients** benefitted through Tele-clinic
- **273+ farmers** positively impacted

1. comparison of FY24 v/s FY19 (Base year)

Vision 2030

Revenue

Reach **2x** from FY24 to FY30

EBITDA Margin

23% to 25% by FY30

Net Debt

Zero by FY30

RoCE

High Teens by FY30



Thanks!

We are open to questions

Glossary

Abbreviation	Details
CVS	Cardiovascular System
CNS	Central Nervous System
CDMO	Contract Development Manufacturing Organization
CRDMO	Contract Research & Development Manufacturing Organization
F18	Fluorine-18 Radioisotope
PSMA	Prostate Specific Membrane Antigen
Lu177	Lutetium-177 Radioisotope
Ac225	Actinium-225 Radioisotope
MAA	Macro Aggregated Albumin
DTPA	Diethylenetriaminepentacetic Acid-Chelating Agent
HICON	Pharmaceutical Grade Radioactive Iodine
I 131	Iodine-131 Radioisotope
MIBG	Metaiodobenzylguanidine
USP (USP 825 Guideline)	U.S. Pharmacopeia (USP) general chapter ,825 (Related to Radiopharmaceuticals: Preparation, Compounding, Dispensing, and Repackaging)
Ga 68	Gallium-68 Radioisotope
Rb	Rubidium (chemical element)
Sr	Strontium (chemical element)
Cu 64	Copper-64 Radioisotope
NRC	Nuclear Regulatory Commission (U.S.)
GPOs	Group Purchasing Organisation
IDNs	Integrated Delivery Network
SCIL	Sublingual immunotherapy (Allergy treatment - Dust mites & Seasonal allergy)
SCIT	Subcutaneous Immunotherapy (Allergy treatment Insect venom, pet dander, Mold, and other allergens)
APAC	Asia Pacific
MEA	Middle East Africa
NSCLC	Non-small cell lung cancer
SCLC	Small cell lung cancer

Abbreviation	Details
MEA	Middle East Africa
LATAM	Latin America
LOE	Loss of exclusivity
FDA (US)	U.S. Food and Drug Administration
PMDA (Japan)	Pharmaceutical and Medical Device Agency
KFDA (Korea)	Korea Food Development Authority
ANVISA (Brazil)	Brazilian Health Regulatory Agency
TGA (Australia)	Therapeutic Goods Administration
API	Active Pharmaceutical Ingredient
MENA	Middle East North Africa
GMP	Good Manufacturing Practices
B2B2C	Business-to-Business-to-Consumer
B2B	Business-to-Business
ET/MPN	Essential thrombocythemia / Myeloproliferative neoplasm (rare chronic blood cancer)
coREST Inhibitor/ Epigenetic Modulating Agent	CRISPR-Cas9 Endomorphic RNA Symptomatic Inhibitor (RNA based therapy targeting genetic disease) Medications that modify gene expression patterns
PRMT5 Inhibitor	Protein Arginine Methyltransferase 5 inhibitor (Blocks enzyme activity involved in adding methyl groups to arginine residues, affecting gene expression regulation)
Brain Penetrant	Cerebral blood flow enhancers or cognitive-enhancing drugs (supplements)
PD-L1 Inhibitor	Programmed death Ligand-1 inhibitor (blocks the PD-L1 pathway, enhancing immune response against cancer cells)
PAD4 Inhibitor	poly(ADP-ribose) polymerase 4 inhibitor (Disrupts DNA repair mechanisms in cancer cells, leading to their death)
LSD1/HDAC6 inhibitor	Lysine specific demethylase 1/Histone deacetylase 6 inhibitor (Blocks enzymes involved in modifying histones, impacting gene expression regulation in cancer therapy)
NSCLC	Non-small cell lung cancer
SCLC	Small cell lung cancer